A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

Completed · Not applicable

Conditions studied: Mycoses, HIV Infections, Coccidioidomycosis

In brief

To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts \< 250 cells/mm3 who are living in the coccidioidal endemic area.

Key facts

Study ID

NCT00002325

Run by

Pfizer

Last updated by the study team

2005-06-24

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Documented HIV infection.
• CD4 count < 250 cells/mm3.
• No active coccidioidomycosis or other fungal disease requiring systemic antifungal therapy.
• Residence in area considered to be endemic for Coccidioides immitis.
• Consent of parent or guardian if under legal age of consent.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Unable to take oral medication.
• Positive serum cryptococcal antigen.
• Concurrent Medication:
• Excluded:
• Systemic antifungal therapy.
• Patients with the following prior conditions are excluded:
• History of hypersensitivity to azole or imidazole compounds.
• Prior Medication:
• Excluded:
• Systemic antifungal agents within 2 weeks prior to study entry.

Where it is running

• McDowell Clinic — Phoenix, Arizona, United States
• Tucson Veterans Administration Med Ctr — Tucson, Arizona, United States
• Dr Lawrence Cone — Rancho Mirage, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.